PROJECT SUMMARY
Leading to over 270,000 deaths in the US annually, septicemia is the systemic inflammatory response to a
bloodstream infection (BSI). Studies have shown that early detection and the administration of appropriate
antimicrobial treatment for BSIs are crucial for proper patient management and lead to improved patient
outcomes and reduced hospitalization times. However, the current diagnostic standard of care relies on blood
culture, which is not only slow, requiring ~1-3 days to return a positive result, but also demonstrates reduced
sensitivity in the presence of antimicrobial treatment. Consequently, there is a substantial demand for innovative
diagnostic approaches that eliminate the need for blood culture and deliver faster and more accurate results.
To address this unmet need, HelixBind developed RaPID/BSI, a fully automated sample-to-answer test which
identifies BSIs directly from blood in four hours, without cultures. Implemented on the RaPID (Resistance and
Pathogen IDentification) platform and appropriate for placement throughout the hospital, RaPID/BSI
incorporates a broad test menu of 20 bacterial and fungal pathogens and, crucially, is not compromised by prior
antimicrobial treatment. Species level detail is provided with single CFUs/ml sensitivity, enabling selection of
appropriate antimicrobials. Commercialization of RaPID/BSI will provide timely characterization of BSIs,
enabling intervention with targeted antimicrobials. This is expected to result in improved patient outcomes and
a reduction in the use of unnecessary antimicrobials, slowing the rise of antimicrobial resistance. Reflecting
RaPID/BSI’s significant advantages over exiting diagnostic standards and the potential to markedly improve
care and quality of life, the FDA designated RaPID/BSI a Breakthrough Technology.
In this proposed Phase II project, HelixBind will complete verification and validation activities necessary to
prepare our submission to the FDA for regulatory clearance. This work includes improvements to the external
control material to be provided with the system along with completion of analytical and clinical studies, as
reviewed with the FDA. Upon successful completion of this project, we will file for regulatory clearance for
RaPID/BSI and bring this breakthrough device to market.
